301 related articles for article (PubMed ID: 16785521)
1. Accumulation of CD8+ T cells in advanced-stage tumors and delay of disease progression following secondary immunization against an immunorecessive epitope.
Ryan CM; Schell TD
J Immunol; 2006 Jul; 177(1):255-67. PubMed ID: 16785521
[TBL] [Abstract][Full Text] [Related]
2. In vivo expansion of the residual tumor antigen-specific CD8+ T lymphocytes that survive negative selection in simian virus 40 T-antigen-transgenic mice.
Schell TD
J Virol; 2004 Feb; 78(4):1751-62. PubMed ID: 14747540
[TBL] [Abstract][Full Text] [Related]
3. Control of advanced choroid plexus tumors in SV40 T antigen transgenic mice following priming of donor CD8(+) T lymphocytes by the endogenous tumor antigen.
Schell TD; Tevethia SS
J Immunol; 2001 Dec; 167(12):6947-56. PubMed ID: 11739514
[TBL] [Abstract][Full Text] [Related]
4. CD8+ T cells targeting a single immunodominant epitope are sufficient for elimination of established SV40 T antigen-induced brain tumors.
Tatum AM; Mylin LM; Bender SJ; Fischer MA; Vigliotti BA; Tevethia MJ; Tevethia SS; Schell TD
J Immunol; 2008 Sep; 181(6):4406-17. PubMed ID: 18768900
[TBL] [Abstract][Full Text] [Related]
5. Inefficient cross-presentation limits the CD8+ T cell response to a subdominant tumor antigen epitope.
Otahal P; Hutchinson SC; Mylin LM; Tevethia MJ; Tevethia SS; Schell TD
J Immunol; 2005 Jul; 175(2):700-12. PubMed ID: 16002665
[TBL] [Abstract][Full Text] [Related]
6. Quantitation of CD8(+) T-lymphocyte responses to multiple epitopes from simian virus 40 (SV40) large T antigen in C57BL/6 mice immunized with SV40, SV40 T-antigen-transformed cells, or vaccinia virus recombinants expressing full-length T antigen or epitope minigenes.
Mylin LM; Schell TD; Roberts D; Epler M; Boesteanu A; Collins EJ; Frelinger JA; Joyce S; Tevethia SS
J Virol; 2000 Aug; 74(15):6922-34. PubMed ID: 10888631
[TBL] [Abstract][Full Text] [Related]
7. Cytotoxic T-lymphocyte epitope immunodominance in the control of choroid plexus tumors in simian virus 40 large T antigen transgenic mice.
Schell TD; Mylin LM; Georgoff I; Teresky AK; Levine AJ; Tevethia SS
J Virol; 1999 Jul; 73(7):5981-93. PubMed ID: 10364350
[TBL] [Abstract][Full Text] [Related]
8. Modification of a tumor antigen determinant to improve peptide/MHC stability is associated with increased immunogenicity and cross-priming a larger fraction of CD8+ T cells.
Watson AM; Mylin LM; Thompson MM; Schell TD
J Immunol; 2012 Dec; 189(12):5549-60. PubMed ID: 23175697
[TBL] [Abstract][Full Text] [Related]
9. Rapid accumulation of adoptively transferred CD8+ T cells at the tumor site is associated with long-term control of SV40 T antigen-induced tumors.
Yorty JL; Tevethia SS; Schell TD
Cancer Immunol Immunother; 2008 Jun; 57(6):883-95. PubMed ID: 18004562
[TBL] [Abstract][Full Text] [Related]
10. In vivo ligation of CD40 enhances priming against the endogenous tumor antigen and promotes CD8+ T cell effector function in SV40 T antigen transgenic mice.
Staveley-O'Carroll K; Schell TD; Jimenez M; Mylin LM; Tevethia MJ; Schoenberger SP; Tevethia SS
J Immunol; 2003 Jul; 171(2):697-707. PubMed ID: 12847236
[TBL] [Abstract][Full Text] [Related]
11. Early immunization induces persistent tumor-infiltrating CD8+ T cells against an immunodominant epitope and promotes lifelong control of pancreatic tumor progression in SV40 tumor antigen transgenic mice.
Otahal P; Schell TD; Hutchinson SC; Knowles BB; Tevethia SS
J Immunol; 2006 Sep; 177(5):3089-99. PubMed ID: 16920946
[TBL] [Abstract][Full Text] [Related]
12. Clonal deletion of simian virus 40 large T antigen-specific T cells in the transgenic adenocarcinoma of mouse prostate mice: an important role for clonal deletion in shaping the repertoire of T cells specific for antigens overexpressed in solid tumors.
Zheng X; Gao JX; Zhang H; Geiger TL; Liu Y; Zheng P
J Immunol; 2002 Nov; 169(9):4761-9. PubMed ID: 12391185
[TBL] [Abstract][Full Text] [Related]
13. Late priming and variability of epitope-specific CD8+ T cell responses during a persistent virus infection.
Kemball CC; Lee ED; Vezys V; Pearson TC; Larsen CP; Lukacher AE
J Immunol; 2005 Jun; 174(12):7950-60. PubMed ID: 15944301
[TBL] [Abstract][Full Text] [Related]
14. Anti-CD40 conditioning enhances the T(CD8) response to a highly tolerogenic epitope and subsequent immunotherapy of simian virus 40 T antigen-induced pancreatic tumors.
Otahal P; Knowles BB; Tevethia SS; Schell TD
J Immunol; 2007 Nov; 179(10):6686-95. PubMed ID: 17982058
[TBL] [Abstract][Full Text] [Related]
15. Elimination of immunodominant epitopes from multispecific DNA-based vaccines allows induction of CD8 T cells that have a striking antiviral potential.
Riedl P; Wieland A; Lamberth K; Buus S; Lemonnier F; Reifenberg K; Reimann J; Schirmbeck R
J Immunol; 2009 Jul; 183(1):370-80. PubMed ID: 19542448
[TBL] [Abstract][Full Text] [Related]
16. Definition of key variables for the induction of optimal NY-ESO-1-specific T cells in HLA transgene mice.
Johannsen A; Genolet R; Legler DF; Luther SA; Luescher IF
J Immunol; 2010 Sep; 185(6):3445-55. PubMed ID: 20733200
[TBL] [Abstract][Full Text] [Related]
17. Early virus-associated bystander events affect the fitness of the CD8 T cell response to persistent virus infection.
Andrews NP; Pack CD; Vezys V; Barber GN; Lukacher AE
J Immunol; 2007 Jun; 178(11):7267-75. PubMed ID: 17513776
[TBL] [Abstract][Full Text] [Related]
18. Flow-microfluorometric monitoring of oligoclonal CD8+ T cell responses to an immunodominant Moloney leukemia virus-encoded epitope in vivo.
Brawand P; Biasi G; Horvath C; Cerottini JC; MacDonald HR
J Immunol; 1998 Feb; 160(4):1659-65. PubMed ID: 9469422
[TBL] [Abstract][Full Text] [Related]
19. Tumor immunity against a simian virus 40 oncoprotein requires CD8+ T lymphocytes in the effector immune phase.
Lowe DB; Shearer MH; Jumper CA; Bright RK; Kennedy RC
J Virol; 2010 Jan; 84(2):883-93. PubMed ID: 19889780
[TBL] [Abstract][Full Text] [Related]
20. Direct presentation regulates the magnitude of the CD8+ T cell response to cell-associated antigen through prolonged T cell proliferation.
Tatum AM; Watson AM; Schell TD
J Immunol; 2010 Sep; 185(5):2763-72. PubMed ID: 20660711
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
